All G2P Projects
The Genomes2People Research Team manages a number of NIH-funded clinical trials in translational genomics and health outcomes, particularly in the areas of genetic risk assessment and disclosure, outcomes of direct-to-consumer personalized genetic testing, and the use of whole genome sequencing in clinical medicine. Click on each project to learn about its goals and progress as well as easily access relevant scientific publications and media stories.
The BabySeq Project, funded by the NIH, is examining the use of whole genome sequencing to screen newborns for genetic childhood disease risk. BabySeq follows the pediatricians’ incorporation of genetic information into the baby’s medical care. BabySeq aims to collect the data needed to examine what the risks and benefits of newborn genome sequencing might be as we imagine implementing into everyday care.
The BabySeq Project, funded by the NIH, is examining the use of whole exome sequencing to screen newborns for genetic childhood disease risk. BabySeq follows the pediatricians’ incorporation of genetic information into the baby’s medical care. BabySeq aims to collect the data needed to examine what the risks and benefits of newborn genome sequencing might be as we imagine implementing into everyday care.
The MilSeq Project, funded by the Department of Defense through the Air Force Medical Support Agency, is a pilot study examining the process of incorporating whole exome sequencing (WES) into the United States Air Force (USAF) military health system. Active-duty service members of the USAF (Airmen) are enrolled into the study to undergo clinical WES.
The Personal Genome Sequencing Outcomes (PeopleSeq) Consortium, funded by the NIH, is one of the first large-scale longitudinal studies to examine the experiences, attitudes and outcomes of apparently healthy adults who have elected to obtain exome or genome sequencing. Data collected will provide valuable information on the potential benefits and costs of performing sequencing in healthy individuals, and key insights into the feasibility of using sequencing to create a more personalized and preventative model of medicine.
Risk Evaluation and Education of Alzheimer’s Disease: the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN), funded by the NIH, is the first multi-site, randomized clinical trial to examine the impact of learning amyloid imaging results in cognitively normal individuals.
The MedSeq Project focused on integrating whole genome sequencing into clinical medicine and was the first clinical trial ever funded by the NIH to empirically study the use of whole genome sequencing in the practice of medicine. The Project was led by a multi-disciplinary team of more than 40 scientists.
The Impact of Personal Genomics (PGen) Study, funded by the NIH, was a survey of consumers from two U.S. companies providing direct-to-consumer genetic testing, using independent third-party data collection and analysis to provide data on who was ordering these tests and why, and potential benefits and risks.
The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study, funded by the NIH, was a series of multi-site randomized controlled clinical trials that provided empirical data to address ethical, social and translational issues in genetic susceptibility testing for common diseases.